ArticleMolecular imaging
Differentiation of glioblastomas from metastatic brain tumors by tryptophan uptake and kinetic analysis: a positron emission tomographic study with magnetic resonance imaging comparison.
Article in Molecular imaging. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 51 citations in OpenAlex.
- Classification of high-grade glioblastoma and single brain metastases using a new SCAT-inception model trained with MRI images.Frontiers in neuroscience · 2024Article
- Review
- Investigational PET tracers in neuro-oncology-What's on the horizon? A report of the PET/RANO group.Neuro-oncology · 2022Article
- Differentiating solitary brain metastases from glioblastoma by radiomics features derived from MRI and 18F-FDG-PET and the combined application of multiple models.Scientific reports · 2022Article
- Artificial intelligence in the radiomic analysis of glioblastomas: A review, taxonomy, and perspective.Frontiers in oncology · 2022Review
- Review
- A common goal to CARE: Cancer Advocates, Researchers, and Clinicians Explore current treatments and clinical trials for breast cancer brain metastases.NPJ breast cancer · 2021Review
- Review
- Depression and tryptophan metabolism in patients with primary brain tumors: Clinical and molecular imaging correlates.Brain imaging and behavior · 2021Article
- An Integrated Radiomics Model Incorporating Diffusion-Weighted Imaging andFrontiers in oncology · 2021Article
- PET imaging in patients with brain metastasis-report of the RANO/PET group.Neuro-oncology · 2019Review
- Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod.Journal of neuro-oncology · 2019Article
- The "pool sign" of metastatic adenocarcinoma.Neuroradiology · 2018Article
- Brain metastases: neuroimaging.Handbook of clinical neurology · 2018Review
- Novel strategies of Raman imaging for brain tumor research.Oncotarget · 2017Article
- Review
- Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.Clinical nuclear medicine · 2017Article
- Assessment of Tryptophan Uptake and Kinetics Using 1-(2-18F-Fluoroethyl)-l-Tryptophan and α-11C-Methyl-l-Tryptophan PET Imaging in Mice Implanted with Patient-Derived Brain Tumor Xenografts.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Article
- Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models of Glioblastoma.Molecular imaging · 2016Article
- Clinical significance of tryptophan metabolism in the nontumoral hemisphere in patients with malignant glioma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Differentiating high-grade gliomas from solitary brain metastases is often difficult by conventional magnetic resonance imaging (MRI); molecular imaging may facilitate such discrimination. We tested the accuracy of α[11C]methyl-l-tryptophan (AMT)-positron emission tomography (PET) to differentiate newly diagnosed glioblastomas from brain metastases. AMT-PET was performed in 36 adults with suspected brain malignancy. Tumoral AMT accumulation was measured by standardized uptake values (SUVs). Tracer kinetic analysis was also performed to separate tumoral net tryptophan transport (by AMT volume of distribution [VD]) from unidirectional uptake rates using dynamic PET and blood input function. Differentiating the accuracy of these PET variables was evaluated and compared to conventional MRI. For glioblastoma/metastasis differentiation, tumoral AMT SUV showed the highest accuracy (74%) and the tumor/cortex VD ratio had the highest positive predictive value (82%). The combined accuracy of MRI (size of contrast-enhancing lesion) and AMT-PET reached up to 93%. For ring-enhancing lesions, tumor/cortex SUV ratios were higher in glioblastomas than in metastatic tumors and could differentiate these two tumor types with > 90% accuracy. These results demonstrate that evaluation of tryptophan accumulation by PET can enhance pretreatment differentiation of glioblastomas and metastatic brain tumors. This approach may be particularly useful in patients with a newly diagnosed solitary ring-enhancing mass.
Indexed as
Identifiers
23759373PMC3804119W2184796245What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.